S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
AI Stock Caught Trading Under Secret Name (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
AI Stock Caught Trading Under Secret Name (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
AI Stock Caught Trading Under Secret Name (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
AI Stock Caught Trading Under Secret Name (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
The Eiffel Tower reopens to visitors after a 6-day closure due to an employee strike
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

$9.77
+0.15 (+1.56%)
(As of 02/23/2024 ET)
Today's Range
$9.50
$9.85
50-Day Range
$8.97
$11.21
52-Week Range
$5.57
$11.26
Volume
328,540 shs
Average Volume
272,779 shs
Market Capitalization
$533.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.44

Marinus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
109.2% Upside
$20.44 Price Target
Short Interest
Healthy
6.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.55
Upright™ Environmental Score
News Sentiment
0.36mentions of Marinus Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.50) to ($2.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.06 out of 5 stars

Medical Sector

175th out of 936 stocks

Pharmaceutical Preparations Industry

76th out of 422 stocks


MRNS stock logo

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Stock Price History

MRNS Stock News Headlines

MRNS Mar 2024 13.000 call
MRNS Mar 2024 10.000 put
Best way to buy gold today (not what you'd think)
With so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion.
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
MRNS Feb 2024 15.000 call
RBC Capital Sticks to Their Buy Rating for Marinus (MRNS)
5 Most Promising Long-Term Stocks According to Analysts
See More Headlines
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/25/2024
Next Earnings (Confirmed)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNS
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.44
High Stock Price Target
$28.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+109.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-19,820,000.00
Net Margins
-432.64%
Pretax Margin
-432.32%

Debt

Sales & Book Value

Annual Sales
$25.48 million
Book Value
$2.26 per share

Miscellaneous

Free Float
51,922,000
Market Cap
$533.15 million
Optionable
Optionable
Beta
0.95
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Scott N. Braunstein M.D. (Age 61)
    CEO, President & Chairman
    Comp: $919.29k
  • Mr. Steven E. Pfanstiel C.M.A. (Age 50)
    M.B.A., COO, CFO & Treasurer
    Comp: $580.35k
  • Dr. Joseph Hulihan M.D. (Age 68)
    Chief Medical Officer
    Comp: $639.51k
  • Dr. Alex Aimetti Ph.D.
    Chief Scientific Officer
  • Ms. Sonya Weigle
    Senior VP of Investor Relations, Human Resources & Corporate Affairs
  • Ms. Martha E. Manning Esq. (Age 69)
    J. D., Senior VP, General Counsel & Secretary
  • Molly Cameron
    Director of Corporate Communications & Investor Relations
  • Dr. Kimberly A. McCormick Pharm.D.
    Chief Regulatory & Quality Assurance Officer
  • Mr. Thomas J. Lyons
    Chief Business Officer
  • Ms. Christina Shafer (Age 48)
    Chief Commercial Officer














MRNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 12 month price objectives for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $9.00 to $28.00. On average, they predict the company's share price to reach $20.44 in the next year. This suggests a possible upside of 109.2% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2024?

Marinus Pharmaceuticals' stock was trading at $10.87 at the start of the year. Since then, MRNS shares have decreased by 10.1% and is now trading at $9.77.
View the best growth stocks for 2024 here
.

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our MRNS earnings forecast
.

How can I listen to Marinus Pharmaceuticals' earnings call?

Marinus Pharmaceuticals will be holding an earnings conference call on Tuesday, March 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.23. The biopharmaceutical company had revenue of $10.11 million for the quarter, compared to the consensus estimate of $2.32 million. Marinus Pharmaceuticals had a negative net margin of 432.64% and a negative trailing twelve-month return on equity of 175.74%. During the same quarter in the prior year, the firm earned ($0.51) EPS.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did Marinus Pharmaceuticals' stock split?

Marinus Pharmaceuticals's stock reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (7.03%), Jennison Associates LLC (5.42%), Vanguard Group Inc. (4.90%), Opaleye Management Inc. (1.03%), abrdn plc (1.01%) and Point72 Asset Management L.P. (0.90%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel.
View institutional ownership trends
.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNS) was last updated on 2/25/2024 by MarketBeat.com Staff